Maxim Comments On Neostem Following KOLs Presentation
In a research report sent to investors today, Maxim Group analyst Jason Kolbert maintained a Buy rating on Neostem (NASDAQ:NBS) with a price target of $15, which represents a potential upside of 297% from where the stock is currently trading.
Kolbert commented: “Yesterday, NeoStem invited Dr. Tim Henry (Cedars Sinai), one of the world’s most preeminent key opinion leaders in cardiology, to present data to a group of buy-side and sell-side analysts. Dr. Henry was joined by Dr. Douglas Losordo, a pioneer in the world of stem cells and cardiology, and Dr. Andrew Pecora, a thought leader in oncology and the pioneer of the Amorcyte (now NeoStem) technology. Opinions vary, and some may claim a bias. However, after spending time with these prominent thought leaders and reviewing the data, our conclusions are unchanged: Enriched CD 34+ cells from bone marrow, at the threshold dose of >14M cells (high dose 20M cells plus), reduces mortality, improves cardiac health, raises ejection fraction, and lowers MACE.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Jason Kolbert has a total average return of 3.3% and a 41.2% success rate. Kolbert has a -22.0% average return when recommending NBS, and is ranked #972 out of 3391 analysts.